AXS Investments’s Haemonetics HAE Stock Holding History

AXS Investments’s Portfolio HAE Stock Details HAE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-885	Closed	-$79.3K	–	410
2023 Q3	$79.3K	Sell	885 -60	-6%	-$5.36K	0.02%	317
2023 Q2	$80.5K	Buy	+945	New	+$79.9K	0.02%	316

Other funds holding HAE

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

AXS Investments's HAE Position: Q4 2023 in Review

AXS Investments sold out of Haemonetics (HAE) in Q4 2023, closing a stake of 885 shares — an estimated $79.3K sold.

AXS Investments first reported a position in HAE in Q2 2023 and held it in 2 quarters. The position peaked at $80.5K in Q2 2023. 295 funds tracked by Wall St. Rank hold HAE as of Q4 2023.

AXS Investments reported no remaining Haemonetics position as of Q4 2023 after selling out during the quarter.
AXS Investments sold 885 Haemonetics shares in Q4 2023, an estimated $79.3K.
AXS Investments first reported a position in Haemonetics in Q2 2023 and held it in 2 quarters.
AXS Investments's Haemonetics position peaked at $80.5K in Q2 2023.
295 funds tracked by Wall St. Rank held Haemonetics as of Q4 2023.

Based on AXS Investments's 13F filing for Q4 2023, filed 9 Feb 2024.